Nautilus Biotechnology Inc at Morgan Stanley Global Healthcare Conference Transcript
Hey, guys. So we're just going to get started here. My name is Tejas Savant. I'm the life science tools and diagnostics analyst here at Morgan Stanley. It's my pleasure to host Sujal Patel from Nautilus and Anna Mowry who's sitting in the audience here, who's the CFO of the company. Before we get started, I just wanted to read the standard disclaimer here. For important disclosures, please see the research website at morganstanley.com/researchdisclosures. And if you have any questions, please do reach out to your sales rep. So with that, Sujal, thank you for doing this.
Questions & Answers
Maybe to start for people in the audience perhaps who are not as familiar with Nautilus, can you just provide a brief history of the company, how it came into being? And what are the key unmet needs in the proteomics market that you are trying to address?
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |